## Criteria-Based Consultation Prescribing Program CRITERIA FOR DRUG COVERAGE

## Cyclosporine 0.09% (Cequa)

## Notes:

- Quantity Limits: No
- Adequate trial is defined as 3 months treatment duration
- \* Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

<u>Initiation (new start) criteria</u>: Non-formulary cyclosporine (Cequa) 0.09% ophthalmic solution will be covered on the prescription drug benefit when the following criteria are met:

- Prescriber is an Ophthalmologist, Optometrist, or Rheumatologist
- Patient has failed an adequate trial<sup>^</sup> of cyclosporine 0.05% ophthalmic emulsion or patient has an allergy or intolerance\* to cyclosporine 0.05% emulsion

Criteria for current Kaiser Permanente members already taking the medication who have not been reviewed previously: Non-formulary cyclosporine (Cequa) 0.09% ophthalmic solution will be covered on the prescription drug benefit when the following criteria are met:

 Patient has failed an adequate trial<sup>^</sup> of cyclosporine 0.05% ophthalmic emulsion or patient has an allergy or intolerance<sup>\*</sup> to cyclosporine 0.05% emulsion

<u>Criteria for new members entering Kaiser Permanente already taking the</u>
<u>medication who have not been reviewed previously</u>: Non-formulary cyclosporine
(Cequa) 0.09% ophthalmic solution will be covered on the prescription drug benefit for when the following criteria are met:

• Patient has failed an adequate trial of cyclosporine 0.05% ophthalmic emulsion or patient has an allergy or intolerance\* to cyclosporine 0.05% emulsion

kp.org

Revised: 02/08/24 Effective: 04/04/24 All plans offered and underwritten by Kaiser Foundation Health Plan of the Northwest

